First premature infant recruited in Kiobrina study - triggers milestone payment from Biovitrum

Biovitrum AB (publ) is in clinical phase II with the Kiobrina project
and the  first preterm  infant has  been recruited.  This triggers  a
milestone payment from Biovitrum.

Kiobrina(TM) is a recombinant, biotechnically produced human enzyme
(BSSL) that breaks down fat in the intestine. Kiobrina is intended as
replacement therapy administered orally to preterm infants to improve
their growth and development. At present, there is no equivalent
treatment available.

BSSL is a very important lipase (enzyme that breaks down fat)
normally found in breast milk. The breast milk pasteurization heating
procedure causes inactivation of BSSL. Consequently, infants who are
given pasteurized breast milk or formula that does not contain BSSL
do not receive this important enzyme. Despite efforts to optimize the
supply of nutrients, preterm infants often suffer from inhibited
growth due to insufficient uptake of fat. Replacement therapy with
recombinant human BSSL could therefore improve the growth of these
infants and have a positive effect on their later development.

With the authority granted  by the Annual General  Meeting of May  3,
2007, the board of directors of Biovitrum has decided in favor of new
issue of no  more than 142,422  new shares, which  will increase  the
company's capital  stock by  maximum  SEK 78,145.50.  Deviating  from
stockholders' right  of  priority,  the  issue  serves  as  milestone
compensation  to  certain  sellers  of  Arexis  AB,  which  Biovitrum
acquired in 2005. The subscription  price amounts to SEK 72.51  which
equals the  average  share  price  for the  last  four  trading  days
preceding the board decision.

About Biovitrum

Biovitrum is a pharmaceutical company  with operations in Sweden  and
in the UK. Biovitrum has currently a research portfolio with  several
projects in  clinical and  preclinical phases  for a  number of  well
defined specialist indications as well as for common diseases  within
obesity, diabetes, inflammation and eye diseases. Biovitrum  develops
and produces protein-based drugs on a contractual basis and markets a
range  of  specialist   pharmaceuticals  primarily   in  the   Nordic
countries. Biovitrum has  revenues of approximately  SEK 1.2  billion
and around  500 employees.  Biovitrum's share  is listed  on the  OMX
Nordic Exchange  in  Stockholm since  September  15, 2006.  For  more
information see www.biovitrum.com.

For more information, please contact:

Biovitrum AB (publ)
Martin Nicklasson,
CEO
Phone: +46 8 697 20 00
martin.nicklasson@biovitrum.com

Erik Kinnman, VP Investor Relations & Public Affairs
Cell phone: +46 734 22 15 40
erik.kinnman@biovitrum.com